Lizoril, tablets 10 mg 28 pcs

Lizoril is an ACE inhibitor. Inhibits the formation of angiotensin II from angeotensin I. Reduces angeotensin II leads to a direct reduction of aldosterone release. Reduces bradykinin degradation and increases prostaglandin synthesis. Reduces total peripheral vascular resistance, BP, preload, pulmonary capillary pressure, causes an increase in cardiac output and increases myocardial tolerance to exercise in patients with heart failure. Dilates arteries more than veins. Some effects are explained by the effect on tissue renin-angiotensin systems.

Long-term use reduces myocardial hypertrophy and arterial resistive walls. It improves the blood supply to the ischemic myocardium. ACE inhibitors prolong life expectancy in patients with heart failure and slow the progression of left ventricular dysfunction in patients who have had myocardial infarction without clinical manifestations of heart failure.

The onset of action is in 1 hour. The maximum effect is determined after 6-7 hours, the duration – 24 hours. In case of arterial hypertension the effect is observed within the first days after the treatment start; the stable action develops within 1-2 months.

Pharmacokinetics

The drug bioavailability is 25-50%, poorly bound to blood plasma proteins. Cmax in blood serum is reached after 7 hours. Absorption is not influenced by food intake.

Permeability through the GEB and the placental barrier is low.

Lisoryl is not metabolized and is excreted unchanged in the urine. Most of it is excreted during the initial phase (effective T1/2 is 12 hours), followed by the terminal distant phase (T1/2 about 30 hours).

Indications

Arterial hypertension, chronic heart failure.

Pharmacological effect

Lizoril is an ACE inhibitor. Suppresses the formation of angiotensin II from angeotensin I. Reduces the content of angiotensin II leads to a direct decrease in the release of aldosterone. Reduces the degradation of bradykinin and increases the synthesis of prostaglandin. Reduces total peripheral vascular resistance, blood pressure, preload, pulmonary capillary pressure, causes an increase in cardiac output and an increase in myocardial tolerance to stress in patients with heart failure. Dilates arteries more than veins. Some effects are explained by effects on tissue renin-angiotensin systems.

With long-term use, hypertrophy of the myocardium and the walls of resistive arteries decreases. Improves blood supply to ischemic myocardium. ACE inhibitors prolong life expectancy in patients with heart failure and slow the progression of left ventricular dysfunction in patients who have suffered a myocardial infarction without clinical manifestations of heart failure.

The onset of action is after 1 hour. The maximum effect is determined after 6-7 hours, duration – 24 hours. For arterial hypertension, the effect is observed in the first days after the start of treatment, a stable effect develops after 1-2 months

Pharmacokinetics

The bioavailability of the drug is 25-50%, weakly bound to blood plasma proteins. Cmax in serum is reached after 7 hours. Eating does not affect absorption.

Permeability through the BBB and placental barrier is low.

Lizoril is not metabolized and is excreted unchanged in the urine. The main part of it is released during the initial phase (effective T1/2 – 12 hours), followed by the terminal late phase (T1/2 about 30 hours)

Special instructions

The drug should be prescribed with caution to patients with impaired renal function, as well as to patients receiving diuretics.
In cases of allergic reactions, treatment with Lizoril should be discontinued.

Control of laboratory parameters

Before starting therapy with Lizoril, it is necessary to monitor laboratory indicators of renal function, water and electrolyte metabolism and, if necessary, compensate for the loss of fluid and salts.

During treatment, the number of blood leukocytes should be periodically monitored, especially in patients with autoimmune and renal diseases, as well as the potassium content in the blood plasma.

Active ingredient

Lisinopril

Composition

Active ingredient:

lisinopril 10 mg.

Excipients:

starch,

mannitol,

dicalcium phosphate dihydrate,

magnesium stearate,

red iron oxide dye.

Contraindications

Hypersensitivity to lisinopril or other ACE inhibitors; history of angioedema, incl. and from the use of ACE inhibitors, hereditary angioedema or idiopathic edema; pregnancy, breastfeeding, age under 18 years (safety and effectiveness have not been determined).

Side Effects

From the nervous system and sensory organs: headache, dizziness.

From the gastrointestinal tract: nausea, vomiting, increased activity of liver transaminases.

From the cardiovascular system and blood (hematopoiesis, hemostasis): hypotension, tachycardia, neutro/thrombocytopenia, decreased hemoglobin levels.

From the respiratory system: dry cough, bronchitis.

Allergic reactions: Quincke’s edema, skin rash.

Other: muscle spasms, hyperkalemia, renal dysfunction.

Interaction

When used simultaneously with NSAIDs, estrogens and sympathomimetics, the effectiveness of Lizoril may decrease.

Combined use with beta blockers, calcium channel blockers, diuretics and other antihypertensive drugs increases the severity of the hypotensive effect of Lizoril.

When Lizoril is used simultaneously with potassium-sparing diuretics, hyperkalemia may develop.

When used together with lithium preparations, Lizoril may slow down the excretion of lithium from the body.

Overdose

Symptoms: arterial hypotension.

Treatment: intravenous administration of isotonic sodium chloride solution, hemodialysis.

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 25 °C

Shelf life

3 years

Manufacturer

Ipka Laboratories Limited, India